|
US4281061A
(en)
|
1979-07-27 |
1981-07-28 |
Syva Company |
Double antibody for enhanced sensitivity in immunoassay
|
|
US6018030A
(en)
|
1986-11-04 |
2000-01-25 |
Protein Polymer Technologies, Inc. |
Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
ES2118066T3
(es)
|
1989-10-05 |
1998-09-16 |
Optein Inc |
Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
PT100379B
(pt)
|
1991-04-10 |
1999-01-29 |
Scripps Research Inst |
Bibliotecas de receptores heterodimericos usando fagomideos
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
JPH07507682A
(ja)
|
1992-05-07 |
1995-08-31 |
アクティノバ・リミテッド |
Lプロテインに由来する免疫グロブリン結合性タンパク質およびその用途
|
|
WO1994012520A1
(en)
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
|
US5643763A
(en)
|
1994-11-04 |
1997-07-01 |
Genpharm International, Inc. |
Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
|
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
|
US5691157A
(en)
|
1995-10-24 |
1997-11-25 |
The Research Foundation Of State University Of New York |
Method for detecting a mammal's prior exposure to radiation or radiomimetic chemicals
|
|
US5846456A
(en)
|
1996-01-17 |
1998-12-08 |
National Science Council |
Method of making gradient index optical element
|
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ,インコーポレイティド |
人工抗体ポリペプチド
|
|
US6670127B2
(en)
|
1997-09-16 |
2003-12-30 |
Egea Biosciences, Inc. |
Method for assembly of a polynucleotide encoding a target polypeptide
|
|
ES2243007T3
(es)
|
1997-09-16 |
2005-11-16 |
Egea Biosciences Llc |
Sintesis quimica completa y sintesis de genes de genomas.
|
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
DE69941267D1
(de)
|
1998-12-10 |
2009-09-24 |
Bristol Myers Squibb Co |
Proteingerüste für antikörper-nachahmer und andere bindende proteine
|
|
US7115396B2
(en)
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US6472147B1
(en)
|
1999-05-25 |
2002-10-29 |
The Scripps Research Institute |
Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
US20130226834A1
(en)
|
2000-04-27 |
2013-08-29 |
Networth Services, Inc. |
Systems and methods for determining the financial status of bonds
|
|
WO2002000692A2
(en)
|
2000-06-28 |
2002-01-03 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
CA2418835A1
(en)
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
GB0119476D0
(en)
|
2001-08-09 |
2001-10-03 |
Novartis Forschungsstiftlung Z |
Anti-tumour agents and method of identifying anti-tumour agents
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
JP4602614B2
(ja)
|
2001-09-26 |
2010-12-22 |
アイシン精機株式会社 |
自動車用ドア
|
|
WO2003037365A1
(en)
|
2001-11-01 |
2003-05-08 |
The Johns Hopkins University |
Methods and compositions for treating vascular leak using hepatocyte growth factor
|
|
WO2003104418A2
(en)
|
2002-06-06 |
2003-12-18 |
Research Corporation Technologies, Inc. |
Reconstituted polypeptides
|
|
AU2003260786B2
(en)
|
2002-09-06 |
2008-03-13 |
Isogenica Limited |
In vitro peptide expression libraray
|
|
WO2004029224A2
(en)
|
2002-09-30 |
2004-04-08 |
Compound Therapeutics, Inc. |
Methods of engineering spatially conserved motifs in polypeptides
|
|
EP2305813A3
(en)
*
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
CA2511910A1
(en)
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
WO2004093892A2
(en)
|
2003-04-16 |
2004-11-04 |
Genentech, Inc. |
Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
|
|
WO2005018534A2
(en)
|
2003-05-16 |
2005-03-03 |
Rosetta Inpharmatics, Llc |
Methods and compositions for rna interference
|
|
DK1661905T3
(da)
|
2003-08-28 |
2012-07-23 |
Takeshi Imanishi |
Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
ES2687645T3
(es)
|
2003-10-27 |
2018-10-26 |
Merck Sharp & Dohme Corp. |
Método de diseño de ARNip para el silenciamiento de genes
|
|
BRPI0417302A
(pt)
|
2003-12-05 |
2007-03-06 |
Compound Therapeutics Inc |
inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
|
|
US20080220049A1
(en)
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
|
US20060040278A1
(en)
|
2004-01-27 |
2006-02-23 |
Cojocaru Gad S |
Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
|
|
AU2005250484B2
(en)
|
2004-06-04 |
2011-08-11 |
Genentech, Inc. |
EGFR mutations
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007047796A2
(en)
*
|
2005-10-17 |
2007-04-26 |
Institute For Systems Biology |
Tissue-and serum-derived glycoproteins and methods of their use
|
|
US7972785B2
(en)
|
2006-01-24 |
2011-07-05 |
Industrial Technology Research Institute (Itri) |
Biomarkers for liver fibrotic injury
|
|
BRPI0710572A2
(pt)
|
2006-01-24 |
2013-01-08 |
Domantis Limited |
ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
|
|
EP2010911A4
(en)
|
2006-03-31 |
2009-05-13 |
Massachusetts Inst Technology |
TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
|
|
FR2903987B1
(fr)
|
2006-07-21 |
2012-12-21 |
Centre Nat Rech Scient |
Nouveaux derives de cyclodextrines amphiphiles, leur utilisation dans les domaines pharmaceutiques,cosmetiques, alimentaires et leur application a la production de nouveaux nanosystemes
|
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
|
WO2008079973A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
|
US20090074828A1
(en)
|
2007-04-04 |
2009-03-19 |
Massachusetts Institute Of Technology |
Poly(amino acid) targeting moieties
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
ES2310122B1
(es)
|
2007-04-20 |
2009-10-30 |
Instituto Cientifico Y Tecnologico De Navarra, S.A |
Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
|
|
US20090042906A1
(en)
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
|
WO2008156642A1
(en)
|
2007-06-15 |
2008-12-24 |
Vasgene Therapeutics, Inc. |
Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
|
|
US20090176654A1
(en)
|
2007-08-10 |
2009-07-09 |
Protelix, Inc. |
Universal fibronectin type III binding-domain libraries
|
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
|
WO2009046294A2
(en)
|
2007-10-03 |
2009-04-09 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
|
EP2215246B1
(en)
|
2007-10-31 |
2015-01-07 |
MedImmune, LLC |
Protein scaffolds
|
|
EP2229186A2
(en)
|
2007-12-04 |
2010-09-22 |
Alnylam Pharmaceuticals Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
AU2008343595A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
A human non-antibody peptide or protein phage library
|
|
JP2011507529A
(ja)
|
2007-12-19 |
2011-03-10 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
M13ファージのpIXへの融合を介する代替の足場タンパク質融合ファージ提示
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
AU2008345424A1
(en)
|
2007-12-27 |
2009-07-09 |
Novartis Ag |
Improved fibronectin-based binding molecules and their use
|
|
EP2247615B1
(en)
|
2008-02-14 |
2014-07-30 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
|
SG188802A1
(en)
|
2008-03-06 |
2013-04-30 |
Genentech Inc |
Combination therapy with c-met and egfr antagonists
|
|
PE20091827A1
(es)
|
2008-04-11 |
2009-11-20 |
Galaxy Biotech Llc |
Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
|
|
CN102076713B
(zh)
|
2008-05-02 |
2015-03-25 |
诺华股份有限公司 |
改进的基于纤连蛋白的结合分子及其用途
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
AU2009300328A1
(en)
|
2008-10-01 |
2010-04-08 |
Ludwig Institute For Cancer Research |
Methods for the treatment of cancer
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
US8394924B2
(en)
|
2008-10-23 |
2013-03-12 |
Massachusetts Institute Of Technology |
Directed engagement of activating Fc receptors
|
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
|
MX2011004550A
(es)
|
2008-10-31 |
2011-07-20 |
Centocor Ortho Biotech Inc |
Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
|
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
CN102596992B
(zh)
|
2009-02-12 |
2015-09-09 |
詹森生物科技公司 |
基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
|
|
WO2010115202A2
(en)
|
2009-04-03 |
2010-10-07 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
|
|
JP6010458B2
(ja)
|
2009-04-03 |
2016-10-19 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. |
非対称二本鎖rnaによる特異的阻害のための、方法および組成物
|
|
CN102361884A
(zh)
|
2009-04-07 |
2012-02-22 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-2/抗-c-Met抗体
|
|
EP2452165A1
(en)
|
2009-07-07 |
2012-05-16 |
Siemens AG |
Apparatus and method for measuring multi-phase fluid flow
|
|
WO2011020033A2
(en)
|
2009-08-13 |
2011-02-17 |
Massachusetts Institute Of Technology |
Engineered proteins including mutant fibronectin domains
|
|
KR101237036B1
(ko)
|
2009-11-04 |
2013-02-25 |
성균관대학교산학협력단 |
안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 siRNA 구조 및 그 용도
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
WO2011100700A2
(en)
|
2010-02-12 |
2011-08-18 |
University Of Rochester |
Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
|
|
EP3904391B1
(en)
|
2010-03-10 |
2024-07-10 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
KR20130056870A
(ko)
|
2010-04-13 |
2013-05-30 |
메디뮨 엘엘씨 |
피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
HUE029622T2
(en)
|
2010-04-30 |
2017-03-28 |
Janssen Biotech Inc |
Stabilized fibronectin domain compositions, methods and uses
|
|
EP3091028A1
(en)
|
2010-05-26 |
2016-11-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
|
AU2011283646B2
(en)
|
2010-07-30 |
2015-07-09 |
Novartis Ag |
Fibronectin cradle molecules and libraries thereof
|
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
|
US20130273561A1
(en)
|
2010-10-29 |
2013-10-17 |
The Governing Council Of The University Of Toronto |
Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
|
|
US20120321666A1
(en)
|
2011-05-23 |
2012-12-20 |
Cooper Laurence J N |
T cell therapy for b cell lymphoma
|
|
WO2012162418A1
(en)
|
2011-05-23 |
2012-11-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for heterodimeric targeting ligands
|
|
US20120315639A1
(en)
|
2011-06-08 |
2012-12-13 |
Glenn Yaguang Deng |
Method and apparatus for single cell isolation and analysis
|
|
MX358827B
(es)
|
2011-09-27 |
2018-09-05 |
Janssen Biotech Inc |
Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
ES2673960T3
(es)
|
2011-12-22 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1)
|
|
RU2577227C1
(ru)
|
2012-01-05 |
2016-03-10 |
Байонир Корпорейшн |
Высокоэффективная двухспиральная олиго-рнк конструкция типа наночастицы и способ ее изготовления
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
CA2874490C
(en)
|
2012-05-23 |
2021-11-16 |
The Ohio State University |
Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same
|
|
JP2015519345A
(ja)
|
2012-05-25 |
2015-07-09 |
ヤンセン バイオテツク,インコーポレーテツド |
非天然コンセンサスアルブミン結合ドメイン
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
US20150191543A1
(en)
|
2012-08-06 |
2015-07-09 |
The Regents Of The University Of California |
Engineered antibody fragments for targeting and imaging cd8 expression in vivo
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
KR102373193B1
(ko)
|
2012-11-21 |
2022-03-10 |
얀센 바이오테크 인코포레이티드 |
이중특이성 EGFR/c-Met 항체
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9433689B2
(en)
|
2013-03-12 |
2016-09-06 |
The Board Of Trustees Of The Leland Stanford Junio |
Probes and methods of imaging non-Hodgkins lymphoma
|
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
WO2015048724A1
(en)
|
2013-09-30 |
2015-04-02 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
|
|
US10196446B2
(en)
|
2013-10-14 |
2019-02-05 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type III domain binding molecules
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
AU2014363987A1
(en)
|
2013-12-09 |
2016-06-30 |
Janssen Biotech, Inc. |
Compositions and methods for phagocyte delivery of anti-staphylococcal agents
|
|
WO2015092394A1
(en)
|
2013-12-17 |
2015-06-25 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
LT3094351T
(lt)
|
2014-01-15 |
2022-04-11 |
Kadmon Corporation, Llc |
Imunitetą moduliuojantys agentai
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
|
AU2015231170B2
(en)
|
2014-03-20 |
2019-10-03 |
Bristol-Myers Squibb Company |
Serum albumin-binding fibronectin type III domains
|
|
US10227394B2
(en)
|
2014-04-08 |
2019-03-12 |
University Of Southern California |
Polypeptide compositions with type VII collagen fibronectin type III-like repeats and treatment methods for wound closure and healing
|
|
US9885721B2
(en)
|
2014-05-29 |
2018-02-06 |
Spring Bioscience Corporation |
PD-L1 antibodies and uses thereof
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
EP3164420A4
(en)
|
2014-06-30 |
2018-05-23 |
Tarveda Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
JP6622814B2
(ja)
|
2014-11-25 |
2019-12-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
イメージングのための新規pd−l1結合ポリペプチド
|
|
WO2016086036A2
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
|
JP7366518B2
(ja)
|
2015-05-06 |
2023-10-23 |
ヤンセン バイオテツク,インコーポレーテツド |
前立腺特異的膜抗原結合フィブロネクチンiii型ドメイン
|
|
EA201792442A1
(ru)
|
2015-05-06 |
2018-06-29 |
Янссен Байотек, Инк. |
Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
|
|
JP2018517708A
(ja)
|
2015-06-05 |
2018-07-05 |
ニューヨーク・ユニバーシティ |
抗ブドウ球菌生物学的薬剤のための組成物及び方法
|
|
WO2017011618A1
(en)
|
2015-07-15 |
2017-01-19 |
The Curators Of The University Of Missouri |
Targeted nanoparticle conjugate and method for co-delivery of sirna and drug
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
CN105907719B
(zh)
|
2016-04-18 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Anti ROBO1 CAR-T细胞及其制备和应用
|
|
EA201892796A1
(ru)
|
2016-06-03 |
2019-06-28 |
Янссен Байотек, Инк. |
Связывающиеся с сывороточным альбумином домены фибронектина типа iii
|
|
AU2017286811A1
(en)
*
|
2016-06-17 |
2018-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
DK3473270T5
(da)
*
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
WO2017223180A2
(en)
|
2016-06-21 |
2017-12-28 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type iii domain binding molecules
|
|
CN109715199A
(zh)
|
2016-09-14 |
2019-05-03 |
詹森生物科技公司 |
包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
|
|
KR102568559B1
(ko)
|
2016-12-14 |
2023-08-18 |
얀센 바이오테크 인코포레이티드 |
Cd8a-결합 섬유결합소 iii형 도메인
|
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
CA3052290A1
(en)
*
|
2017-02-10 |
2018-08-16 |
The Rockefeller University |
Methods for cell-type specific profiling to identify drug targets
|
|
CA3082204A1
(en)
|
2017-12-13 |
2019-06-20 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
CA3098623A1
(en)
*
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
AU2019310097A1
(en)
*
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
|
EP4013428A4
(en)
|
2019-08-15 |
2023-08-09 |
Ionis Pharmaceuticals, Inc. |
MODIFIED OLIGOMER COMPOUNDS AND USES THEREOF
|
|
KR20220062517A
(ko)
|
2019-08-15 |
2022-05-17 |
아이오니스 파마수티컬즈, 인코포레이티드 |
결합 변형된 올리고머 화합물 및 이의 용도
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
US20230330246A1
(en)
|
2020-05-05 |
2023-10-19 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
EP4308095A4
(en)
|
2021-03-15 |
2025-02-19 |
Maze Therapeutics, Inc. |
GLYCOGEN SYNTHASE 1 (GYS1) INHIBITORS AND METHODS OF USE THEREOF
|
|
KR20240009393A
(ko)
|
2021-03-31 |
2024-01-22 |
엔트라다 테라퓨틱스, 인크. |
사이클릭 세포 침투 펩티드
|
|
KR20240031947A
(ko)
|
2021-04-14 |
2024-03-08 |
에이알오 바이오테라퓨틱스 컴패니 |
Fn3 도메인-시르나 접합체 및 이의 용도
|
|
JP2024517610A
(ja)
*
|
2021-04-14 |
2024-04-23 |
アロ・バイオセラピューティクス・カンパニー |
Cd71に結合するフィブロネクチンiii型ドメイン
|
|
WO2023201362A2
(en)
|
2022-04-14 |
2023-10-19 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates with enzyme replacement therapy
|
|
US20250368997A1
(en)
|
2022-05-06 |
2025-12-04 |
Aro Biotherapeutics Company |
Compositions and Methods for GYS1 Inhibition
|